

**NOUVEAU LIFE PHARMACEUTICALS, INC.**  
**CONSOLIDATED FINANCIALS**  
**UNAUDITED**  
**2015 Annual**

**BALANCE SHEET**

ASSETS

|                     |                               |
|---------------------|-------------------------------|
| Current             |                               |
| Cash                | 1,941                         |
| Accounts Receivable | 11,976                        |
| Fixed Asset         | -                             |
| Inventory Asset     | (78,604)                      |
| <b>TOTAL ASSETS</b> | <b><u><u>(64,687)</u></u></b> |

LIABILITIES

|                          |                              |
|--------------------------|------------------------------|
| Current                  |                              |
| Loan                     | 10,000                       |
| Sales Tax Payable        | 1,953                        |
| Notes Payable            | 196,368                      |
| <b>Total Liabilities</b> | <b><u><u>208,321</u></u></b> |

STOCKHOLDERS' EQUITY

|  |                                |
|--|--------------------------------|
| SHARE CAPITAL  |                                |
| Common shares, 2,000,000,000 authorized, par value \$0.0001 -<br>Issued and outstanding, December 31, 2015 - 1,989,999,733 | 199,000                        |
| Preferred shares, 10,000,000 authorized<br>Issued and outstanding, December 31, 2015 - 10,000,000                          | 1,000                          |
| Accumulated Deficit  | (473,008)                      |
| Shareholders net gain (loss)   | <b><u><u>(273,008)</u></u></b> |
| <b>TOTAL LIABILITIES AND SHAREHOLDERS EQUITY</b>   | <b><u><u>(64,687)</u></u></b>  |

**NOUVEAU LIFE PHARMACEUTICALS, INC.**  
**CONSOLIDATED FINANCIALS**  
**UNAUDITED**  
**2015 Annual**

**BALANCE SHEET**

**STATEMENTS OF EARNINGS**

REVENUE

|               |                       |
|---------------|-----------------------|
| Income        | 254,854               |
| Cost of Sales | <u>7,897</u>          |
| Gross Margin  | <u><u>246,957</u></u> |

OPERATING EXPENSES

|                                     |                |
|-------------------------------------|----------------|
| Selling, general and administrative | 314,553        |
| Total Operating Expenses            | <u>314,553</u> |

NET GAIN (LOSS) (59,699)

|  |               |
|--|---------------|
| Weighted Average Number of Common Shares     | 1,989,999,733 |
| Net Loss Per Share - Basic and Fully Diluted | (0.00)        |

**CASH FLOWS FROM OPERATING ACTIVITIES**

|                                    |             |
|------------------------------------|-------------|
| Net loss                           | \$ (59,699) |
| Stock issued for services rendered | -           |
| Stock issued for cash              | -           |
| Changes in assets and liabilities  | -           |
| Accounts payable                   | <u>-</u>    |

NET CASH FLOWS FROM (USED IN) OPERATING ACTIVITIES (59,699)

**CASH FLOWS FROM FINANCING ACTIVITIES**

|                             |   |
|-----------------------------|---|
| Advances by(to) shareholder | - |
| Share capital issued        | - |

**NET CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES**

|  |       |
|--|-------|
| Cash and Cash Equivalents - beginning of quarter | 1,433 |
| Cash and Cash Equivalents - end of quarter       | 1,941 |
| Net Change In Cash                               | 3,374 |

**NOUVEAU LIFE PHARMACEUTICALS, INC.**  
**CONSOLIDATED FINANCIALS**  
**UNAUDITED**  
**2015 Annual**

**BALANCE SHEET**  
**STOCKHOLDERS' EQUITY**

|                              | Common<br>Shares | Stock<br>Amount | Additional Paid<br>In Capital |
|------------------------------|------------------|-----------------|-------------------------------|
|                              | <hr/>            |                 |                               |
| Balance December 31, 2014    | 1,989,999,733    | 199,000         |                               |
| Stock issued for services    | -                | -               |                               |
| Stock issued for cash        | -                | -               |                               |
| Stock issued for acquisition | -                | -               |                               |
| Balance December 31, 2015    | 1,989,999,733    | 199,000         |                               |

**NOUVEAU LIFE PHARMACEUTICALS, INC.**  
**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**  
**December 31, 2015**  
**(Unaudited)**

**NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:**

**a) Basis of Presentation:**

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. At the balance sheet date, the Company has a stockholders' deficiency and a deficit accumulated during the development stage. Management plans to issue more shares of common stock in order to raise funds.

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with generally accepted accounting principles. In the opinion of management, these financial statements include all adjustments necessary in order to make them not misleading.

**b) Use of Estimates:**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**c) Cash and Cash Equivalents:**

For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with maturity of three months or less to be cash equivalents.

**d) Income taxes:**

The Company utilizes the liability method of accounting for income taxes. Under the liability method deferred tax assets and liabilities are determined based on the differences between financial reporting basis and the tax basis of the assets and liabilities and are measured using enacted tax rates and laws that will be in effect, when the differences are expected to reverse. An allowance against deferred tax assets is recognized, when it is more likely than not, that such tax benefits will not be realized.

Any deferred tax asset is considered immaterial and has been fully offset by a valuation allowance because at this time the Company believes that it is more likely than not that the future tax benefit will not be realized as the Company has no current operations.

**e) Loss per Common Share:**

Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.

**f) Fair Value of Financial Instruments:**

The carrying value of cash, due from affiliate and due to shareholder approximate their fair value due to the short period of time to maturity.

**g) Comprehensive Income:**

Comprehensive income (loss) is not presented in the Company's financial statements since there is no difference between net loss and comprehensive loss in any period presented.

## **NOTE 2 - CAPITAL STOCK**

The total number of shares of capital stock, which the Company shall have authority to issue, is 2,000,000,000 shares common shares par value \$0.0001. Holders of shares of common stock are entitled to cast one vote for each share held at all stockholders' meetings for all purposes, including the election of directors. The common stock does not have cumulative voting rights.

## **NOTE 3 - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS**

We adopted the provisions of the FASB Statement on Generally Accepted Accounting Principles ("GAAP") relating to the FASB Accounting Standards Codification ("Codification") on DECEMBER 31, 2009. This Statement establishes the Codification as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission ("SEC") under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead, the FASB will issue Accounting Standards Updates.

## **NOTE 4 - INCOME TAXES**

The Company has incurred net losses and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved.

## **NOTE 5 - GOING CONCERN**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the accompanying financial statements, the Company incurred losses since its inception and has not produced enough revenues from operations. These factors raise substantial doubt about the Company's ability to continue as a going concern.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern. Management anticipates that it will be able to raise additional working capital through the issuance of stock and through additional loans from investors.

The ability of the Company to continue as a going concern is dependent upon the Company's ability to attain a satisfactory level of profitability and obtain suitable and adequate financing. There can be no assurance that management's plan will be successful.

## **NOTE 6 – NOTES PAYABLE**

The Company has convertible notes dated June 30, 2012, August 30, 2012 and October 15, 2012, in the amount of \$75,000, \$75,000 and \$46,368 respectively.

## **NOTE 7 - LACK OF INSURANCE**

The Company could be exposed to liabilities or other claims for which the Company would have no insurance protection. The Company does not currently maintain any property insurance, business interruption insurance, products liability insurance, or any other comprehensive insurance policy. Any purchaser of the Company's common stock could lose their entire investment should uninsured losses occur.